Najeeda Yasmeen, BSc (Hons)
Najeeda is a Senior Health Outcomes Researcher. Since joining Symmetron in October 2015, she has gained experience in systematic reviews and network meta-analysis, in areas including psoriasis, ulcerative colitis, endometriosis and haemophilia B. Najeeda has a BSc in Biomedical Sciences from University College London. After graduating, Najeeda also interned at a Healthcare Communications agency.
Wright E, Yasmeen N, Malottki K, Sawyer LM, Borg E, Schwenke C, Warren RB. Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us? Dermatol Ther (Heidelb). 2020 Dec 22. doi: 10.1007/s13555-020-00463-y. Epub ahead of print. PMID: 33351178.
Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year [published online ahead of print, 2020 Apr 2]. J Dermatolog Treat. 2020;1-15. doi:10.1080/09546634.2020.1743811
Wright E, Yasmeen N, Malottki K, Sawyer L, et al. Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us? Value in Health, 2019; 22, S908.
Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868. Published 2019 Aug 14. doi:10.1371/journal.pone.0220868
Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat. 2018;29(6):557-568. doi:10.1080/09546634.2018.1427205
Sawyer L, Fotheringham I, Cornic L, Yasmeen N, et al. Assessing the Longer-Term Efficacy of Biologic Therapies and Apremilast for Patients with Moderate-To-Severe Psoriasis: A Systematic Review and Network Meta-Analysis. Value in Health, 2017; 20, A801.